This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Inari unenforceability counterclaims against Corteva get green light in US

By Melissa Ritti ( May 14, 2025, 14:05 GMT | Insight) -- Corteva Agriscience cannot shake a counterclaim by Inari Agriculture which seeks a declaration of unenforceability with regard to 231 Corteva utility patents Inari is not accused of infringing. Because the unasserted patents claim the same “event” — the insertion of a particular transgene into a particular location in a plant chromosome — as a Corteva patent which Inari is alleged to infringe, Corteva’s “broadside against Inari’s misappropriation creates an immediate and concrete controversy,” a US judge ruled yesterday. His decision should give other Plant Variety Protection certificate holders pause and could nudge the parties into settling their burgeoning feud.Inari Agriculture’s sprawling expansion, via counterclaim, of infringement litigation by Corteva Agriscience has succeeded in part, with a Delaware federal judge finding a justiciable connection between a patent asserted by Corteva and hundreds of other patents which are not....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections